(S045) Equivalent Survival With Breast-Conserving Therapy and Mastectomy in Young Women Under the Age of 40 With Early-Stage Breast Cancer: A National Registry-Based Stage-by-Stage Comparison

OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Our study suggests that while young age may be a poor prognostic factor for breast cancer, there is no evidence that these patients have better outcomes with mastectomy over BCT, supporting the continued use of BCT.

Jason C. Ye, MD, Weisi Yan, MD, PhD, Paul Christos, DrPH, MS, Dattatreyudu Nori, MD, MBBS, Akkamma Ravi, MD, MBBS; Department of Radiation Oncology, New York Presbyterian Hospital/Weill Cornell Medical College; Department of Radiation Oncology, New York Hospital Queens/Weill Cornell Medical College; Division of Biostatistics & Epidemiology, Department of Public Health, Weill Cornell Medical College

PURPOSE: Studies have shown that young patients with early-stage breast cancer (BC) are increasingly getting mastectomy instead of breast-conserving therapy (BCT) despite the lack of clear survival evidence in this approach. We examined the difference between outcomes in young women (aged < 40 yr) treated with BCT vs mastectomy.

METHODS: The Surveillance, Epidemiology, and End Results (SEER) database was queried for women aged < 40 years and diagnosed with stage I or II invasive BC treated with surgery from 1998–2003. Breast cancer–specific survival (BCSS) and overall survival (OS) were evaluated by Kaplan-Meier survival analysis, and the log-rank test was used to compare survival between treatment categories of interest. Multivariable Cox regression model analysis was performed to estimate the predictors of BCSS.

RESULTS: Of the 7,665 women identified, 3,249 (42%) received BCT, while 2,627 (34%) patients had mastectomy and no radiation. There were also 994 (14%) patients who had lumpectomy but no radiation, and 795 (10%) were treated with mastectomy plus radiation. On multivariate analysis, higher stage, estrogen receptor–negative status, and mastectomy plus radiation were found to have a higher risk of BC mortality. When separated by stage, with a median follow-up of 111 months (based on living patients), the BCT and mastectomy-only groups showed no statistically significant difference in BCSS or OS. There was also no difference in non-BC mortality in any-stage disease between the two treatment groups. The group aged 35–39 years (66% of total) was associated with better 10-year BCSS (88%) and OS (86.1%) compared with patients aged 20–34 years (34% of total), who had 10-year BCSS and OS rates of 84.1% and 82.3%, respectively (P < .001 for both BCSS and OS). When patients of each age group were further subdivided into stages I, IIA, and IIB, there was no statistically significant difference in BCSS or OS between the BCT and mastectomy groups for any stage for those aged 35–39 years or for stages I and IIA in the 20–34-year-old age group. However, in patients aged 20–34 years with stage IIB disease only, the mastectomy-only group (n = 183) had significantly inferior 10-year BCSS (64% vs 79%; P = .004) and OS (61% vs 77%; P = .002) compared with the BCT group (n = 183).

CONCLUSION: Our study suggests that while young age may be a poor prognostic factor for breast cancer, there is no evidence that these patients have better outcomes with mastectomy over BCT, supporting the continued use of BCT.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Related Content